logo
Brain Computer Interface Market is Poised to Hit Valuation of US$ 11.20 Billion by 2033

Brain Computer Interface Market is Poised to Hit Valuation of US$ 11.20 Billion by 2033

Yahoo30-04-2025

The brain computer interface market is accelerating due to non-invasive accessibility, AI-driven diagnostics, and metaverse integration. Healthcare demand and consumer adoption dominate growth, with North America leading innovation while APAC addresses scalability amid ethical and cost challenges.
Chicago, April 30, 2025 (GLOBE NEWSWIRE) -- The global brain computer interface market was valued at US$ 2.84 billion in 2024 and is anticipated to reach US$ 11.20 billion by 2033, growing at a CAGR of 16.43% during the forecast period 2025–2033.
Brain-Computer Interface (BCI) technologies have evolved significantly in recent years, transitioning from basic laboratory prototypes to sophisticated commercial solutions. In 2024, industry witnesses increased convergence of AI, machine learning, and neural networks, enhancing usability, accuracy, and responsiveness. Notably, invasive BCIs, such as Neuralink's implantable devices, have progressed to human clinical trials, demonstrating promising preliminary results in treating neurological disorders like paralysis and epilepsy. Meanwhile, non-invasive solutions employing EEG (Electroencephalogram) and fNIRS (functional Near-Infrared Spectroscopy) have gained traction, attributed to their safety, ease of use, and improved signal processing capabilities.
Download Sample Pages:
The consumer has also begun embracing brain computer interface market, with companies like NextMind and Emotiv offering affordable, wearable EEG headsets for gaming, education, and virtual reality applications. Additionally, significant advancements in haptic feedback and immersive virtual environments have enabled seamless integration of BCI technology into the metaverse, creating engaging neuro-interactive experiences. The evolution of cloud-based neural data analytics platforms has further enabled real-time data processing and user-specific calibration, making BCIs accessible to broader demographics. As technology continues to mature, ongoing cross-disciplinary collaboration among neuroscience, computer science, and engineering fields is anticipated to foster further innovation, driving the BCI market trajectory upward in the foreseeable future.
Key Findings in Brain Computer Interface Market
Market Forecast (2033)
US$ 11.20 billion
CAGR
16.43%
Largest Region (2024)
North America (35%)
By Component
Hardware (57%)
By Type
Non-Invasive BCI (86%)
By Application
Healthcare (49%)
Top Drivers
Increasing adoption of non-invasive brain-computer interfaces across multiple sectors.
Rising healthcare applications addressing neurological disorders and patient rehabilitation needs.
Significant venture capital investment accelerating neurotechnology research and innovation.
Top Trends
Integration of artificial intelligence enhancing accuracy of neural decoding.
Expansion of consumer-grade wearable neurotech into gaming and metaverse.
Growing strategic partnerships among neurotech startups and leading technology companies.
Top Challenges
High device cost limiting widespread adoption in developing regions worldwide.
Complex regulatory approval processes delaying commercialization timelines for products.
Ethical concerns and user data privacy issues hindering customer acceptance.
Emerging Trends: Future Technological Innovations in Brain-Computer Interface Domain
In 2024, emerging technological trends in the brain computer interface market are focused on enhancing usability, connectivity, and integration with complementary technologies. One significant trend is the growing adoption of multimodal neuroimaging, combining EEG, fNIRS, and magnetoencephalography (MEG), enabling more accurate, real-time insights into brain activity. Companies such as Kernel and OpenBCI are actively exploring integration of these modalities into wearable, consumer-friendly devices, significantly expanding application possibilities beyond traditional clinical settings.
Another critical trend is the increasing utilization of artificial intelligence and machine learning algorithms to improve signal processing, classification accuracy, and user-specific customization. Advanced AI-driven neural decoding techniques developed by Neuralink and Synchron have significantly elevated invasive BCI performance, facilitating precise control of prosthetics, computers, and robotic devices. Additionally, wireless, battery-free neurotech solutions leveraging energy-efficient communication protocols, such as Bluetooth Low Energy (BLE) and Near-Field Communication (NFC), are gaining momentum, streamlining user experiences and promoting broader adoption. The integration of BCIs into immersive virtual environments, particularly within the rapidly expanding metaverse, is another prominent trend, creating enhanced neuro-interactive experiences and opening avenues for unprecedented cognitive interactions. Collectively, these emerging technological innovations signal a bright future for the BCI industry, characterized by enhanced capabilities, broader applications, and improved accessibility.
Non-Invasive BCI Solutions Driving Robust Market Adoption and Industry Growth
Non-invasive brain computer interface market have emerged as transformative solutions, reshaping market dynamics through rapid adoption across diverse sectors, including healthcare, gaming, education, and workplace productivity. By 2025, non-invasive BCIs leveraging advanced EEG (Electroencephalography), fNIRS (functional Near-Infrared Spectroscopy), and hybrid modalities have captured nearly 75% of the total BCI market share, according to recent analysis from Astute Analytica. This surge is largely attributable to improved signal processing algorithms, AI-driven calibration methods, and user-friendly wearable designs, significantly enhancing usability and consumer acceptance. Companies such as Emotiv, NextMind (recently acquired by Snap Inc.), and Kernel have successfully commercialized EEG-based headsets and helmets, facilitating real-time cognitive monitoring, neurofeedback training, and hands-free device control, thus driving widespread adoption among tech-savvy consumers and enterprises alike.
Furthermore, robust investment inflows into non-invasive BCIs underscore industry confidence, with global venture capital funding surpassing US$ 1.2 billion in 2024 alone, marking a 45% increase compared to 2023 in the brain computer interface market. Strategic partnerships between BCI manufacturers and major technology companies, notably Snap Inc., Meta, and Microsoft, have further accelerated market penetration, embedding neurotechnology into platforms spanning virtual reality, metaverse interactions, and remote work tools. Additionally, increased regulatory clarity and supportive policies in major markets, including the FDA's streamlined pathways for neurotech approvals, have significantly mitigated market entry barriers, enticing new startups and investors to explore non-invasive opportunities. As consumer comfort and familiarity with wearable neurotech rise, non-invasive BCIs are positioned to maintain robust growth, redefining human-technology interactions in the coming decade.
Regional Insights: Market Penetration and Potential Across Global Geographic Regions
The global Brain computer interface marketdisplays notable regional variations influenced by technological infrastructure, regulatory frameworks, and investment climates. North America continues to dominate the BCI landscape, driven primarily by the United States, where substantial venture capital funding, progressive FDA regulatory support, and robust research institutions accelerate commercialization. Recent initiatives, including DARPA's Neural Engineering System Design (NESD) program and NIH's BRAIN initiative, significantly bolster local industry growth, creating ample opportunities for innovative companies to thrive.
Europe follows closely behind, with Germany, Switzerland, and the United Kingdom leading advancements in medical-focused BCI applications. Germany's BrainGate initiative and UK-based BIOS Health's neurotech platforms exemplify Europe's strength in clinical-grade neuro-interface technologies, supported by favorable regulatory environments under the European Medical Device Regulation (MDR). Meanwhile, Asia-Pacific is rapidly emerging as a promising growth region, led by China, Japan, and South Korea, witnessing increased governmental investments in neurotech research and development, especially in consumer and healthcare segments. Chinese companies, exemplified by BrainCo, have successfully commercialized EEG-based neurofeedback headbands for educational purposes, indicating significant market potential. Looking forward, sustained investments, supportive policies, and rising public awareness in these regions are poised to drive substantial market expansion over the coming years.
Investment Opportunities: Lucrative Market Segments Within Brain-Computer Interface Industry
The Brain computer interface market in 2024 presents lucrative investment opportunities across several key segments, notably healthcare and consumer applications. Within healthcare, neurorehabilitation and assistive technology applications are particularly attractive, addressing unmet medical needs in paralysis, stroke recovery, and neurodegenerative diseases. Companies like Synchron and Neuralink have demonstrated substantial progress, indicating significant long-term potential for investors seeking impactful healthcare innovations. Furthermore, therapeutic and diagnostic applications utilizing advanced neuroimaging, real-time neural data analytics, and AI-driven predictive models represent additional high-growth segments with considerable ROI potential.
The consumer segment in the brain computer interface market, encompassing gaming, virtual reality, and wellness, also presents compelling investment opportunities. Rapid adoption of wearable EEG headsets from companies like Emotiv and NextMind among gaming enthusiasts highlights consumer willingness to embrace innovative neurotech solutions. Additionally, the emerging market for cognitive enhancement and stress management applications, exemplified by Kernel's Flow platform and Muse's meditation EEG headbands, indicates growing consumer demand for neurotechnology-driven wellness solutions. Venture capitalists and institutional investors increasingly recognize the BCI industry's potential, particularly in startups integrating BCIs with metaverse technologies and immersive virtual environments. Thus, strategic investments directed toward pioneering firms in healthcare and consumer segments promise substantial financial and societal returns in the foreseeable future.
Ask for a Tailored Report:
Competitive Landscape: Analysis of Prominent Players in BCI Industry Worldwide
The brain computer interface market's competitive landscape in 2024 is diverse, comprising established industry giants, innovative startups, and academic spin-offs. Neuralink, backed by Elon Musk, remains prominent, recently showcasing successful human trials of implantable BCIs that facilitate intuitive control of digital devices. Synchron, another key invasive BCI player, has also advanced, earning FDA Breakthrough Device designation for its endovascular Stentrode device, which shows promise for patients with severe motor impairments. On the non-invasive front, Emotiv continues to lead with affordable EEG headsets, extensively utilized in research, gaming, and healthcare applications, emphasizing user-friendly design and robust software ecosystems.
Emerging startups in the brain computer interface market such as NextMind, recently acquired by Snap Inc. in early 2023, highlight the trend of major tech companies entering the BCI domain, recognizing its substantial market potential. Kernel, a California-based neurotech company, has introduced Kernel Flow—a helmet utilizing fNIRS technology to measure brain activity with high spatial resolution, targeting consumer wellness and cognitive enhancement markets. Additionally, OpenBCI's open-source hardware and software approach has captured significant attention within academic and research communities, fostering collaborative innovation. Strategic partnerships among these players, substantial R&D investments, and intellectual property developments are expected to intensify competition, shaping the BCI industry's trajectory over the next decade.
Global Brain Computer Interface Market Major Players:
Neuralink
Synchron
Emotiv
NeuroSky
Paradromics
Bitbrain
Neurable
Brain Products GmbH
Kernel
Other Prominent Players
Key Segmentation:
By Component
Hardware
Software
Services
By Type
Invasive BCI
Non-Invasive BCI
Partially Invasive BCI
By Application
Healthcare
Gaming & Entertainment
Smart Home Control
Education & Research
Military & Defense
Others
By Region
North America
Europe
Asia Pacific
Middle East & Africa (MEA)
South America
Request Additional Details Before Purchase:
About Astute Analytica
Astute Analytica is a global market research and advisory firm providing data-driven insights across industries such as technology, healthcare, chemicals, semiconductors, FMCG, and more. We publish multiple reports daily, equipping businesses with the intelligence they need to navigate market trends, emerging opportunities, competitive landscapes, and technological advancements.
With a team of experienced business analysts, economists, and industry experts, we deliver accurate, in-depth, and actionable research tailored to meet the strategic needs of our clients. At Astute Analytica, our clients come first, and we are committed to delivering cost-effective, high-value research solutions that drive success in an evolving marketplace.
Contact Us:Astute AnalyticaPhone: +1-888 429 6757 (US Toll Free); +91-0120- 4483891 (Rest of the World)For Sales Enquiries: sales@astuteanalytica.comWebsite: https://www.astuteanalytica.com/ Follow us on: LinkedIn | Twitter | YouTube
CONTACT: Contact Us: Astute Analytica Phone: +1-888 429 6757 (US Toll Free); +91-0120- 4483891 (Rest of the World) For Sales Enquiries: sales@astuteanalytica.com Website: https://www.astuteanalytica.com/

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Kenyan government has revealed plans to adopt the Danish F2 platform
Kenyan government has revealed plans to adopt the Danish F2 platform

Business Upturn

time5 minutes ago

  • Business Upturn

Kenyan government has revealed plans to adopt the Danish F2 platform

By GlobeNewswire Published on June 6, 2025, 11:57 IST Press Release no. 03/2025 Kenyan government has revealed plans to adopt the Danish F2 platform Copenhagen, June 6, 2025 cBrain (NASDAQ: CBRAIN) is pleased to share that the Kenyan Ministry of Information, Communications, and the Digital Economy has revealed plans to roll out the F2 digital platform across all government departments, thereby transitioning into paperless working environments. The plans were shared with Kenyan media by Cabinet Secretary William Kabogo on June 4, following a high-level meeting with the Danish Ambassador to Kenya, Stephan Schønemann. The project is being implemented with support from the Danish government, and cBrain is proud to contribute its technology to this strategic collaboration. According to the Cabinet Secretary, the new digital platform will be fundamental in reinforcing transparency and accountability in the Kenyan public service. 'To ensure efficient service delivery, the government requires clear processes and decision-making that can be traced, transparent, accountable, and timely. This is fundamental to ensure every action is fully auditable,' he told the media. This comes two months after the Cabinet Secretary told the media that the Ministry was piloting a paperless system, aiming to eliminate bureaucracies that slow down service delivery. F2 is a commercial off-the-shelf (COTS) digital platform designed specifically for government use, developed in close collaboration with the Danish government. F2 serves as the digital backbone for Denmark's central administration and is actively used by the Danish ministries and more than 75 Danish government organizations. Internationally, the F2 COTS for government platform has been deployed by government authorities across five continents. Purpose-built to support public sector workflows, compliance, and documentation needs, F2 enables fast, scalable, and legally compliant digital operations across the public sector. Best regards Per Tejs Knudsen, CEO Inquiries regarding this Press Release may be directed to Ejvind Jørgensen, CFO & Head of Investor Relations, cBrain A/S, [email protected], +45 2594 4973 Attachment Press Release no 2025-03 (Kenyan government has revealed plans to adopt F2) Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Business Upturn takes no editorial responsibility for the same. GlobeNewswire provides press release distribution services globally, with substantial operations in North America and Europe.

Burning Rock Reports First Quarter 2025 Financial Results
Burning Rock Reports First Quarter 2025 Financial Results

Yahoo

time28 minutes ago

  • Yahoo

Burning Rock Reports First Quarter 2025 Financial Results

GUANGZHOU, China, June 06, 2025 (GLOBE NEWSWIRE) -- Burning Rock Biotech Limited (NASDAQ: BNR, the 'Company' or 'Burning Rock'), a company focused on the application of next generation sequencing (NGS) technology in the field of precision oncology, today reported financial results for the three months ended March 31, 2025. Recent Business Updates Therapy Selection and MRD Personalized Minimal Residual Disease (MRD) product, CanCatch® Custom supports advancement in oesophageal squamous cell carcinoma(OSCC)treatment, with results published in the Molecular Cancer in May 2025. The study is a two-arm, multicenter, randomized, double-blind phase 2 study, comparing the efficacy of systemic treatment combining nCT with immunotherapy against nCT alone for OSCC patients. The study demonstrates that Perioperative Nivolumab plus chemotherapy is a viable and safe option for systemically treating locally advanced resectable OSCC, and monitoring minimal residual disease through ctDNA could be potentially valuable for assessing the effectiveness of adjuvant therapy and for prognostic evaluation in a systemic manner. Presented study results on non-small cell lung cancer and gastrointestinal stromal tumor (GIST) at the ASCO in June 2025. 'Personalized tumor-informed ctDNA has the potential to inform recurrence in high-risk locally advanced stage GIST patients, especially for patients with irregular adjuvant therapy' and 'MUSETALK-Lung01 (MUltiomics SEquencing Technique AppLication Kick-start) is a prospective, longitudinal, observational study designed to evaluate the clinical utility of a tumor-naïve ctDNA assay in patients with early-stage non-small cell lung cancer (NSCLC).' Presented multiple study results at the 2025 AACR in April, showcasing the clinical utility of the tumor-informed personalized MRD assay (CanCatch® Custom) and the tumor-naïve methylation-based MRD assay. First Quarter 2025 Financial Results Revenues were RMB133.1 million (US$18.3 million) for the three months ended March 31, 2025, representing a 5.9% increase from RMB125.6 million for the same period in 2024. Revenue generated from central laboratory business was RMB38.3 million (US$5.3 million) for the three months ended March 31, 2025, representing a 19.6% decrease from RMB47.6 million for the same period in 2024, primarily attributable to a decrease in the number of tests, as we continued to focus on our in-hospital business. Revenue generated from in-hospital business was RMB57.7 million (US$7.9 million) for the three months ended March 31, 2025, representing a 0.5% increase from RMB57.4 million for the same period in 2024, driven by a continuous growth in sales volume. Revenue generated from pharma research and development services was RMB37.1 million (US$5.1 million) for the three months ended March 31, 2025, representing a 79.9% increase from RMB20.6 million for the same period in 2024, primarily attributable to increased development and testing services performed for our pharma customers, and several milestones of our pharma programs were achieved. Cost of revenues was RMB35.7 million (US$4.9 million) for the three months ended March 31, 2025, representing a 10.6% decrease from RMB39.9 million for the same period in 2024, primarily due to a decrease in cost of central laboratory business, which was in line with the decrease in revenue generated from this business. Gross profit was RMB97.4 million (US$13.4 million) for the three months ended March 31, 2025, representing a 13.7% increase from RMB85.7 million for the same period in 2024. Gross margin was 73.2% for the three months ended March 31, 2025, compared to 68.2% for the same period in 2024. By channel, gross margin of central laboratory business was 84.1% for the three months ended March 31, 2025, compared to 77.7% during the same period in 2024, primarily due to a reduction in material and labor costs resulted from cost optimization and control measures and a decreased depreciation and rental cost in relation to our laboratory of Guangzhou headquarter; gross margin of in-hospital business was 76.1% for the three months ended March 31, 2025, compared to 68.3% during the same period in 2024, primarily due to the same reason; gross margin of pharma research and development services was 57.5% for the three months ended March 31, 2025, compared to 46.1% during the same period of 2024, primarily due to the cost optimization measures and an increase in test volume of higher margin projects. Non-GAAP gross profit, which excludes depreciation and amortization expenses, RMB100.7 million (US$13.9 million) for the three months ended March 31, 2025, representing an 8.3% increase from RMB93.0 million for the same period in 2024. Non-GAAP gross margin was 75.6% for the three months ended March 31, 2025, compared to 74.0% for the same period in 2024. Operating expenses were RMB112.6 million (US$15.5 million) for the three months ended March 31, 2025, representing a 46.8% decrease from RMB211.5 million for the same period in 2024. The decrease was primarily driven by budget control measures and headcount reduction to improve the Company's operating efficiency. Research and development expenses were RMB40.4 million (US$5.6 million) for the three months ended March 31, 2025, representing a 38.8% decrease from RMB66.0 million for the same period in 2024, primarily due to (i) a decrease in amortized expense on share-based compensation; (ii) a decrease in the expenditure for detection research and (iii) a decrease in depreciation and amortization. Selling and marketing expenses were RMB40.9 million (US$5.6 million) for the three months ended March 31, 2025, representing a 12.7% decrease from RMB46.9 million for the same period in 2024, primarily due to (i) a decrease in staff cost resulted from the reorganization of our sales department to improve operating efficiency and (ii) a decrease in depreciation and amortization. General and administrative expenses were RMB31.3 million (US$4.3 million) for the three months ended March 31, 2025, representing a 68.3% decrease from RMB98.7 million for the same period in 2024, primarily due to (i) a decrease in amortized expense on share-based compensation; (ii) a decrease in depreciation and amortization; (iii) a decrease in staff cost resulted from the reorganization; and (iv) a decrease in operating lease expense for office building. Net loss was RMB13.5 million (US$1.9 million) for the three months ended March 31, 2025, compared to RMB121.5 million for the same period in 2024. Cash, cash equivalents and restricted cash were RMB497.4 million (US$68.5 million) as of March 31, 2025. Exchange Rate Information This press release contains translations of certain Renminbi amounts into U.S. dollars at a specified rate solely for the convenience of the reader. Unless otherwise noted, all translations from Renminbi to U.S. dollars and from U.S. dollars to Renminbi are made at a rate of RMB7.2567 to US$1.00, the exchange rate on March 31, 2025, set forth in the H.10 statistical release of the Federal Reserve Board. The Company makes no representation that the Renminbi or U.S. dollars amounts referred could be converted into U.S. dollars or Renminbi, as the case may be, at any particular rate or at all. About Burning Rock Burning Rock Biotech Limited (NASDAQ: BNR), whose mission is to guard life via science, focuses on the application of next generation sequencing (NGS) technology in the field of precision oncology. Its business consists of i) NGS-based therapy selection testing for late-stage cancer patients, and ii) cancer early detection, which has moved beyond proof-of-concept R&D into the clinical validation stage. For more information about Burning Rock, please visit: Safe Harbor Statement This press release contains forward-looking statements. These statements constitute 'forward-looking' statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and as defined in the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as 'will,' 'expects,' 'anticipates,' 'future,' 'intends,' 'plans,' 'believes,' 'estimates,' 'target,' 'confident' and similar statements. Burning Rock may also make written or oral forward-looking statements in its periodic reports to the SEC, in its annual report to shareholders, in press releases and other written materials and in oral statements made by its officers, directors or employees to third parties. Statements that are not historical facts, including statements about Burning Rock's beliefs and expectations, are forward-looking statements. Such statements are based upon management's current expectations and current market and operating conditions, and relate to events that involve known or unknown risks, uncertainties and other factors, all of which are difficult to predict and many of which are beyond Burning Rock's control. Forward-looking statements involve risks, uncertainties and other factors that could cause actual results to differ materially from those contained in any such statements. All information provided in this press release is as of the date of this press release, and Burning Rock does not undertake any obligation to update any forward-looking statement as a result of new information, future events or otherwise, except as required under applicable law. Non-GAAP Measures In evaluating the business, the Company considers and uses non-GAAP measures, such as non-GAAP gross profit and non-GAAP gross margin, as supplemental measures to review and assess operating performance. The presentation of these non-GAAP financial measures is not intended to be considered in isolation or as a substitute for the financial information prepared and presented in accordance with accounting principles generally accepted in the United States of America ('U.S. GAAP'). The company defines non-GAAP gross profit as gross profit excluding depreciation and amortization. The company defines non-GAAP gross margin as gross margin excluding depreciation and amortization. The company presents these non-GAAP financial measures because they are used by management to evaluate operating performance and formulate business plans. The company believe non-GAAP gross profit and non-GAAP gross margin excluding non-cash impact of depreciation and amortization reflect the company's ongoing business operations in a manner that allows more meaningful period-to-period comparisons. Contact: IR@ Selected Operating Data As of March 31, 2024 June 30, 2024 September 30, 2024 December 31, 2024 March 31, 2025 In-hospital Channel: Pipeline partner hospitals(1) 28 29 30 29 30 Contracted partner hospitals(2) 59 59 61 63 63 Total number of partner hospitals 87 88 91 92 93(1) Refers to hospitals that are in the process of establishing in-hospital laboratories, laboratory equipment procurement or installation, staff training or pilot testing using the Company's products. (2) Refers to hospitals that have entered into contracts to purchase the Company's products for use on a recurring basis in their respective in-hospital laboratories the Company helped them establish. Kit revenue is generated from contracted hospitals. Selected Financial Data For the three months ended Revenues March 31, 2024 June 30, 2024 September 30, 2024 December 31, 2024 March 31, 2025 (RMB in thousands) Central laboratory channel 47,614 48,773 39,984 39,278 38,296 In-hospital channel 57,387 59,872 63,769 43,464 57,687 Pharma research and development channel 20,622 26,888 24,891 43,280 37,099 Total revenues 125,623 135,533 128,644 126,022 133,082 For the three months ended Gross profit March 31,2024 June 30,2024 September 30,2024 December 31,2024 March 31,2025 (RMB in thousands) Central laboratory channel 37,002 38,424 33,262 33,153 32,191 In-hospital channel 39,192 44,058 46,580 29,563 43,895 Pharma research and development channel 9,500 12,956 12,004 26,706 21,315 Total gross profit 85,694 95,438 91,846 89,422 97,401 For the three months ended Share-based compensation expenses March 31,2024 June 30,2024 September 30,2024 December 31,2024 March 31,2025 (RMB in thousands) Cost of revenues 596 464 289 520 308 Research and development expenses 12,287 12,008 3,180 3,202 1,800 Selling and marketing expenses 508 1,232 1,917 1,353 1,025 General and administrative expenses 55,990 54,407 4,732 2,937 1,413 Total share-based compensation expenses 69,381 68,111 10,118 8,012 4,546 Burning Rock Biotech Limited Unaudited Condensed Statements of Comprehensive Loss (in thousands, except for number of shares and per share data) For the three months ended March 31,2024 June 30,2024 September 30, 2024 December 31,2024 March 31, 2025 March 31, 2025 RMB RMB RMB RMB RMB US$ Revenues 125,623 135,533 128,644 126,022 133,082 18,340 Cost of revenues (39,929 ) (40,095 ) (36,798 ) (36,600 ) (35,681 ) (4,918 ) Gross profit 85,694 95,438 91,846 89,422 97,401 13,422 Operating expenses: Research and development expenses (65,985 ) (64,952 ) (49,150 ) (52,203 ) (40,389 ) (5,566 ) Selling and marketing expenses (46,856 ) (48,907 ) (48,411 ) (46,730 ) (40,888 ) (5,635 ) General and administrative expenses (98,681 ) (92,794 ) (32,874 ) (37,289 ) (31,303 ) (4,314 ) Impairment loss on long-lived assets (35,127 ) Total operating expenses (211,522 ) (206,653 ) (130,435 ) (171,349 ) (112,580 ) (15,515 ) Loss from operations (125,828 ) (111,215 ) (38,589 ) (81,927 ) (15,179 ) (2,093 ) Interest income 4,038 3,187 3,173 1,814 2,581 356 Other income (expense), net 434 (82 ) 1 4,353 (652 ) (90 ) Foreign exchange (loss) gain, net (13 ) 262 (129 ) (220 ) (26 ) (4 ) Loss before income tax (121,369 ) (107,848 ) (35,544 ) (75,980 ) (13,276 ) (1,831 ) Income tax expenses (180 ) (190 ) (201 ) (5,314 ) (224 ) (31 ) Net loss (121,549 ) (108,038 ) (35,745 ) (81,294 ) (13,500 ) (1,862 ) Net loss attributable to Burning Rock Biotech Limited's shareholders (121,549 ) (108,038 ) (35,745 ) (81,294 ) (13,500 ) (1,862 ) Net loss attributable to ordinary shareholders (121,549 ) (108,038 ) (35,745 ) (81,294 ) (13,500 ) (1,862 ) Loss per share for class A and class B ordinary shares: Class A ordinary shares - basic and diluted (1.19 ) (1.05 ) (0.35 ) (0.79 ) (0.13 ) (0.02 ) Class B ordinary shares - basic and diluted (1.19 ) (1.05 ) (0.35 ) (0.79 ) (0.13 ) (0.02 ) Weighted average shares outstanding used in loss per share computation: Class A ordinary shares - basic and diluted 85,219,188 85,271,858 85,902,670 86,036,286 90,291,658 90,291,658 Class B ordinary shares - basic and diluted 17,324,848 17,324,848 17,324,848 17,324,848 17,324,848 17,324,848 Other comprehensive income (loss), net of tax of nil: Foreign currency translation adjustments 590 940 (4,054 ) 6,009 (72 ) (10 ) Total comprehensive loss (120,959 ) (107,098 ) (39,799 ) (75,285 ) (13,572 ) (1,872 ) Total comprehensive loss attributable to Burning Rock Biotech Limited's shareholders (120,959 ) (107,098 ) (39,799 ) (75,285 ) (13,572 ) (1,872 ) Burning Rock Biotech LimitedUnaudited Condensed Consolidated Balance Sheets(In thousands) As of December 31, 2024 March 31,2025 March 31,2025 RMB RMB US$ ASSETS Current assets: Cash and cash equivalents 519,849 495,145 68,233 Restricted cash 2,313 2,261 312 Accounts receivable, net 152,013 159,463 21,974 Contract assets, net 13,855 17,178 2,367 Inventories, net 62,625 65,424 9,016 Prepayments and other current assets, net 25,963 22,072 3,042 Total current assets 776,618 761,543 104,944 Non-current assets: Property and equipment, net 47,152 41,162 5,672 Operating right-of-use assets 53,188 43,804 6,036 Intangible assets, net 421 386 53 Other non-current assets 7,926 7,822 1,078 Total non-current assets 108,687 93,174 12,839 TOTAL ASSETS 885,305 854,717 117,783 Burning Rock Biotech LimitedUnaudited Condensed Consolidated Balance Sheets (Continued)(in thousands) As of December 31,2024 March 31,2025 March 31,2025 RMB RMB US$ LIABILITIES AND SHAREHOLDERS' EQUITY Current liabilities: Accounts payable 33,747 35,938 4,952 Deferred revenue 117,895 117,200 16,151 Accrued liabilities and other current liabilities 89,498 76,198 10,501 Customer deposits 592 592 82 Current portion of operating lease liabilities 24,567 22,524 3,104 Total current liabilities 266,299 252,452 34,790 Non-current liabilities: Non-current portion of operating lease liabilities 27,754 19,814 2,730 Other non-current liabilities 10,425 10,649 1,467 Total non-current liabilities 38,179 30,463 4,197 TOTAL LIABILITIES 304,478 282,915 38,987 Shareholders' equity: Class A ordinary shares 124 124 17 Class B ordinary shares 21 21 3 Additional paid-in capital 5,002,255 5,005,991 689,844 Treasury stock (63,264 ) (62,453 ) (8,606 ) Accumulated deficits (4,200,261 ) (4,213,761 ) (580,672 ) Accumulated other comprehensive loss (158,048 ) (158,120 ) (21,790 ) Total shareholders' equity 580,827 571,802 78,796 TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY 885,305 854,717 117,783 Burning Rock Biotech LimitedUnaudited Condensed Statements of Cash Flows(in thousands) For the three months ended March 31,2024 March 31,2025 March 31,2025 RMB RMB US$ Net cash generated from (used in) operating activities 19,062 (23,527 ) (3,242 ) Net cash used in investing activities (812 ) (1,531 ) (211 ) Net cash used in financing activities (74 ) - - Effect of exchange rate on cash, cash equivalents and restricted cash 5,739 302 43 Net increase in (decrease) cash, cash equivalents and restricted cash 23,915 (24,756 ) (3,410 ) Cash, cash equivalents and restricted cash at the beginning of period 498,247 522,162 71,955 Cash, cash equivalents and restricted cash at the end of period 522,162 497,406 68,545 Burning Rock Biotech LimitedReconciliations of GAAP and Non-GAAP Results For the three months ended March 31,2024 June 30,2024 September 30,2024 December 31,2024 March 31,2025 (RMB in thousands) Gross profit: Central laboratory channel 37,002 38,424 33,262 33,153 32,191 In-hospital channel 39,192 44,058 46,580 29,563 43,895 Pharma research and development channel 9,500 12,956 12,004 26,706 21,315 Total gross profit 85,694 95,438 91,846 89,422 97,401 Add: depreciation and amortization: Central laboratory channel 1,919 1,226 1,277 1,010 562 In-hospital channel 1,524 824 798 623 290 Pharma research and development channel 3,856 4,417 3,846 2,534 2,412 Total depreciation and amortization included in cost of revenues 7,299 6,467 5,921 4,167 3,264 Non-GAAP gross profit: Central laboratory channel 38,921 39,650 34,539 34,163 32,753 In-hospital channel 40,716 44,882 47,378 30,186 44,185 Pharma research and development channel 13,356 17,373 15,850 29,240 23,727 Total non-GAAP gross profit 92,993 101,905 97,767 93,589 100,665 Non-GAAP gross margin: Central laboratory channel 81.7% 81.3% 86.4% 87.0% 85.5% In-hospital channel 70.9% 75.0% 74.3% 69.5% 76.6% Pharma research and development channel 64.8% 64.6% 63.7% 67.6% 64.0% Total non-GAAP gross margin 74.0% 75.2% 76.0% 74.3% 75.6%Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

How much damage could Donald Trump do to Elon Musk?
How much damage could Donald Trump do to Elon Musk?

CNN

timean hour ago

  • CNN

How much damage could Donald Trump do to Elon Musk?

Tesla stock soared in the months after the November presidential election because investors were convinced Donald Trump was about to do massive favors for his largest financial backer, Tesla CEO Elon Musk. But Trump can also do great damage to Musk's many business interests. The risk of that damage is one reason that Tesla shares (TSLA) tumbled 14% in trading Thursday following the very nasty and public spat between Trump and Musk. But it's not just Tesla that could be at risk. SpaceX depends on government contracts for a significant share of its revenue. And Tesla, SpaceX and Musk's other companies, including social media platform X, artificial intelligence company xAI and brain-computer interface company Neuralink all face regulation from the federal government. In addition, Musk faces possible investigations of his own activities from agencies such as the Securities and Exchange Commission, which is looking into whether he violated rules when purchased his initial stake in X, then called Twitter, ahead of launching his takeover bid for the company. Trump appeared to threaten that he would take such action against Musk, as he posted on his Truth social media platform Thursday that, 'The easiest way to save money in our Budget, Billions and Billions of Dollars, is to terminate Elon's Governmental Subsidies and Contracts. I was always surprised that Biden didn't do it!' To which Musk replied on his social media platform X: 'This just gets better and better,' followed by two laughing face emojis, along with 'Go ahead, make my day.' Tesla has relatively few government contracts. But there are numerous federal policies that directly affect its finances, including a $7,500 tax credit for electric vehicle buyers that allows Tesla and other automakers to raise prices. That was likely worth billions to Tesla last year alone. In addition, Tesla reported more than $8 billion in sales over six years of regulatory credits to other automakers to help them comply with federal and state emission standards. Trump is in favor of rolling back those standards and stripping states of the power to set their own emissions rules, which would destroy the market for those credit sales. A note from JPMorgan to clients Thursday estimates the loss of the EV tax credit could cost Tesla $1.2 billion a year and the loss of regulatory credit sales another $2 billion. Musk has also pegged the future of the growth of Tesla on operating a self-driving taxi service without any driver on board. Tesla's current 'full self driving' offering (FSD) requires a driver to be present to take control of the car. The service is due to debut in Austin, Texas, later this month. He admits his ambitious growth plans could be constrained by regulations. In addition, the federal National Highway Traffic Safety Administration has also already announced investigations into accidents involving existing Tesla cars operating with FSD. Many Tesla fans assumed those investigations would be dropped under a Tesla-friendly Trump administration. SpaceX has received $15.2 billion in contracts from NASA, as well as $5.8 billion from the Department of Defense, along with a few million more from other agencies, according to Replacing SpaceX on those contracts, however, is not realistic. That's because there is no other company available to replace it. For example, Boeing, the only other company able transport astronauts to and from the International Space Station (ISS), had problems on its only crewed flight last year. That required its Starliner spacecraft to return to Earth without two astronauts, who were stranded at the ISS for nine months instead of the planned trip of a handful of days. But SpaceX also is subject to the oversight of both NASA and the FAA. Its Starlink satellite internet communication service is also seeking approval from the FCC to expand its service.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store